Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
57.7% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
27
users have liked this narrative
8
users have commented on this narrative
76
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.0% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
35
users have liked this narrative
6
users have commented on this narrative
97
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.6% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Magna International
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
China Expansion And Operational Improvements Will Lead To Future Success
Key Takeaways Magna International's operational excellence and restructuring actions aim for margin expansion, positively affecting net margins, earnings, and free cash flow generation. Strategic focus on growth in China and share repurchases could boost revenue, EPS, and overall financial performance.
View narrative
CA$65.80
FV
11.1% undervalued
intrinsic discount
1.71%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
59
users have followed this narrative
Updated
narrative
Ionis Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 26 Analysts
Escalating Payer Pressures Will Crush Margins Despite Fleeting Pipeline Optimism
Key Takeaways Revenue growth and profit margins are threatened by pricing pressures, regulatory scrutiny, and reliance on narrow indications and select partnerships. High competition, rising costs, and uncertain market adoption may lead to persistent operating losses and volatile financial performance.
View narrative
US$38.00
FV
9.6% overvalued
intrinsic discount
1.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
SiTime
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
AI Infrastructure Growth Will Intensify Overcapacity And Supply Risks
Key Takeaways Intensifying competition and rapid industry investment threaten SiTime with supply-demand imbalances, shrinking markets, and margin pressures as technology evolves. Overreliance on key customers and high R&D costs, combined with geopolitical risks, create earnings volatility and long-term revenue uncertainty.
View narrative
US$180.00
FV
10.9% overvalued
intrinsic discount
35.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
SentinelOne
AN
AnalystLowTarget
Consensus Narrative from 35 Analysts
Mounting Regulatory Costs And Open-Source Competition Will Hurt Cybersecurity Markets
Key Takeaways Rising compliance costs, regulatory hurdles, and industry consolidation threaten SentinelOne's revenue growth, margins, and long-term relevance in the cybersecurity market. Persistent R&D and sales spending, coupled with strong competition and customer budget sensitivity, may undermine profitability and limit operating margin improvement.
View narrative
US$17.00
FV
5.7% undervalued
intrinsic discount
19.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Comtech Telecommunications
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Transformation Will Reinforce Operations And Open Cloud And Satellite Markets
Key Takeaways Comtech's transformation plan aims to enhance profitability through operational improvements, cost management, and high-margin initiatives. Strategic alliances and divestitures could enhance earnings and financial flexibility amidst growth in satellite and wireless segments.
View narrative
US$6.00
FV
n/a
intrinsic discount
-2.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
GitLab
AN
AnalystLowTarget
Consensus Narrative from 27 Analysts
Fragmenting DevOps Pipelines Will Undermine Future Profitability
Key Takeaways Proliferation of AI tools, bundled competitor offerings, and architectural trends threaten GitLab's platform relevance, pricing power, and overall market opportunity. Rising regulatory demands and relentless innovation spending increase costs, challenging profitability and long-term earnings growth.
View narrative
US$45.00
FV
10.2% undervalued
intrinsic discount
21.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
MongoDB
AN
AnalystLowTarget
Consensus Narrative from 37 Analysts
Rising Regulatory Pressures And Hyperscaler Competition Will Squeeze Margins
Key Takeaways Regulatory burdens, increasing competition, and shifting industry trends threaten MongoDB's ability to scale, pricing power, and long-term revenue expansion. High investment needs and reliance on consumption-based pricing heighten earnings volatility and are likely to keep margins depressed.
View narrative
US$193.28
FV
8.2% overvalued
intrinsic discount
14.39%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
DATAGROUP
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
European GDPR Mandates And IT Talent Shortages Will Compress Margins
Key Takeaways Regulatory burdens and talent shortages are driving up costs, eroding margins, and weakening DATAGROUP's scalability and profit outlook. Industry shifts toward automation and consolidation threaten DATAGROUP's core market, shrinking growth prospects and increasing vulnerability to economic downturns.
View narrative
€54.00
FV
10.9% overvalued
intrinsic discount
3.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
PTC Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Key Takeaways Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues. Strong financial collaboration with Novartis positions PTC for substantial earnings growth through milestones, profit sharing, and royalties.
View narrative
US$67.44
FV
32.7% undervalued
intrinsic discount
-12.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies